N
NeuroVision
Biotech & Life Sciences · Sacramento, United States · Founded 2010
Detecting neurodegenerative diseases MoreLess
NeuroVision is a pioneering company in the healthcare sector, specializing in the development of proprietary blood tests and advanced retinal imaging software. These innovations are designed to track key neurological biomarkers and ocular features, providing critical feedback to clinicians and motivation to patients. The company's blood tests aim to delay the onset of cognitive decline by enabling lifestyle risk reduction, while its retinal imaging software helps doctors identify and manage retinal diseases more effectively. NeuroVision collaborates closely with pharmaceutical companies to explore complementary and companion biomarker opportunities. The company primarily serves healthcare providers, clinicians, and pharmaceutical firms, operating in the medical diagnostics and biotechnology markets. NeuroVision's business model revolves around the development and commercialization of its diagnostic tools, generating revenue through partnerships, licensing agreements, and direct sales of its products.
Keywords: neurological biomarkers, retinal imaging, cognitive decline, blood tests, ocular features, healthcare providers, pharmaceutical collaborations, medical diagnostics, biotechnology, lifestyle risk reduction.
Company overview
NeuroVision company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2010
- Headquarters
- Sacramento, United States
- Employees
- 21
- Open positions
- None listed
- Dealroom signal
- 82.5
- Investment activity
- 1 companies · latest May 2026
- Capital deployed
- —
- Preferred round
- ACQUISITION
Valuation & funding
NeuroVision funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Aug 2021 | $0 | — | Alzheimer's Drug Discovery Foundation | — |
| GRANTOther financing | Feb 2021 | — | — | Alzheimer's Drug Discovery Foundation | — |
| SERIES C✓Equity / VC | May 2018 | $11M | $45M | Wildcat Capital Management · Wildcat Capital Management | ↗ |
| SERIES BEquity / VC | Jun 2016 | $10M | $40M | Wildcat Capital Management | — |
| OtherOther financing | Jan 2014 | $0 | — | Undisclosed | — |
| SPINOUT✓Other financing | Jan 2010 | Cedars-Sinai | — |
Financials
Revenue and workforce over time
Available revenue and workforce history. Fields without reported data are omitted.
| Year | Revenue | Growth | Employees |
|---|---|---|---|
| 2026 | $975K | 0% | 22 |
| 2025 | $975K | 0% | 17 |
| 2024 | $975K | 0% | 11 |
| 2023 | $975K | 0% | 9 |
| 2022 | $975K | 0% | 10 |
| 2021 | $975K | — | 12 |
Growth signals
NeuroVision website traffic
Latest recorded traffic for NeuroVision is 3K monthly website visits, up 130.8% over the last three months. NeuroVision's team grew 23.5% over the past year.
Comparisons
NeuroVision compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
NeuroVision investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
NeuroVision's talent
Source: Dealroom Talent Intelligence.
Investors
4 investors on NeuroVision's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where NeuroVision has talent and traffic
team presence
In the news
Latest news about NeuroVision
Recent press, funding announcements, and product moves mentioning NeuroVision — open to read from the original sources.
Market sentiment
What the market is saying about NeuroVision
An AI-synthesized read of the highest-engagement posts about NeuroVision on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NeuroVision’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.